Press Release

Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June

NEW YORK, June 10, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that Dr. Andrew Vaillant, Chief Scientific Officer will be presenting at two scientific conferences in June.

Dr. Vaillant has been invited to attend the Israel Association for the Study of Liver conference on June 11 where he will speak on Application of Nucleic Acid Polymers for the Treatment of HBV and HDV Infection.

Dr. Vaillant will also attend the Global Virus Hepatitis Summit in Berlin, Germany June 26-28 where he will present “REP 2139 monotherapy and combination therapy with pegylated interferon: Safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV / HDV co-infection.” This important conference on the international calendar for the study of hepatitis and liver diseases occurs every three years. Dr. Vaillant will present updated clinical data, subsequent to the data presented at EASL ILC conference in Vienna on April 24.

“These data continue to demonstrate the validity of our thesis for the treatment of hepatitis B and D and further validate the efficacy and safety of REP 2139 observed in the previous three Asian clinical trials,” said Dr. Vaillant.

The data from the previous three clinical trials, together with the preliminary data from the REP 301 trial, demonstrate that REP 2139 used alone or in combination with Pegasys® or ZADAXIN® or Pegasys® and ETV is safe and well-tolerated. In these trials the antiviral response to REP 2139, when used as a backbone therapy in combination with various immunotherapies was profound, with up to 7 log HBsAg reductions or clearance, with accompanying ≥ 6 log reductions or clearance of HBV DNA or HDV RNA. In HBV infected patients, this combination approach appears to significantly increase the 12-month SVR rate achieved when compared to existing therapies.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.

Media Contact:

Alexandra Peterson
apeterson@makovsky.com
212-508-9709